OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS

Podobne zapisy

• 3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
  od: McCormick, D, i wsp.
  Wydane: (2009)
• Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes.
  od: Davies, L, i wsp.
  Wydane: (2008)
• EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
  od: Davies, J, i wsp.
  Wydane: (2009)
• REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
  od: Alton, E, i wsp.
  Wydane: (2012)
• Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
  od: Alton, E, i wsp.
  Wydane: (2012)